Figure 4
From: The functional and inflammatory response of brain endothelial cells to Toll-Like Receptor agonists
Analysis of hCMVEC responsiveness to TLR7 ligand Loxoribine and PCR of TLR 3, 7 and 4. (a) The TLR7 agonist Loxoribine 25 µg/mL (red) 5 µg/mL, (green), 1 µg/ml (blue), and untreated media-only control (black) was administered to confluent hCMVECs 48 hours post-seeding on an xCELLigence 96 well plate, indicated by the red arrow. Data shown has been normalized (100%) prior to the addition of ligands (raw data shown in Supplemental Fig. 5). Curves represent the mean ± SD of three individual wells, (normalised prior to addition of ligands) and are representative of at least three independent experiments. (b) PCR of untreated hCMVEC cDNA for TLR 3, 7 and 4. RT+ indicates the presence of reverse transcriptase. cDNA from human PBMC was used as the positive control. PCR products were separated by agarose gel electrophoresis and visualized using RedSafe. A 100 bp DNA ladder was used for amplicon sizing. Images are representative of at least three independent experiments.
